Dr Rebecca Kristeleit is a distinguished medical oncologist specialising in gynaecological cancers, including cervical, endometrial, and ovarian cancer. She joined Guy's and St Thomas' NHS Foundation Trust in early 2020, transitioning from UCL to spearhead the expansion of clinical and translational research in gynaecological oncology. Dr Kristeleit is renowned for her expertise in novel therapies and molecular testing, having played a pivotal role in the approval of new drugs such as rucaparib, lurbinectedin, and dostarlimab.

Dr Kristeleit completed her medical degree at the University of Manchester in 1995, following a BSc in medical science from the University of St Andrews. She further honed her skills with a CRUK-funded clinical research fellowship at the Institute of Cancer Research, earning a PhD in the clinical pharmacology of HDAC inhibitors. Her career includes a Senior Fellowship at the Royal Marsden Hospital's Drug Development Unit, where she gained significant experience in experimental therapeutics.

In addition to her clinical roles, Dr Kristeleit is an active member of several prestigious boards and committees, including the Target Ovarian Cancer Scientific Advisory Board and the Oncology and Haematology Expert Advisory Group for the Commission on Human Medicines. She has been elected to the ESMO Faculty from 2021 to 2025 and has over 100 peer-reviewed publications. Dr Kristeleit is frequently invited to speak at national and international conferences and advises pharmaceutical companies on gynaecological cancer drug development.

Her clinical interests include immunotherapy for gynaecological malignancies, and she leads a comprehensive portfolio of Phase I-III clinical studies. Dr Kristeleit is dedicated to advancing the field of gynaecological oncology through both her clinical practice and research initiatives.